Avatrombopag

TargetMol
Product Code: TAR-T7417
Supplier: TargetMol
CodeSizePrice
TAR-T7417-1mg1mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-2mg2mg£138.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-5mg5mg£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-1mL1 mL * 10 mM (in DMSO)£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-10mg10mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-25mg25mg£357.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-50mg50mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-100mg100mg£755.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7417-500mg500mg£1,460.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.
CAS:
570406-98-3
Formula:
C29H34Cl2N6O3S2
Molecular Weight:
649.65
Pathway:
Immunology/Inflammation; Proteases/Proteasome
Purity:
0.9941
SMILES:
OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1
Target:
Thrombin; Thrombopoietin Receptor

References

Al-Samkari H.Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.Drugs Today (Barc). 2018 Nov;54(11):647-655. Xu H, Cai R.Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.Expert Rev Clin Pharmacol. 2019 Sep;12(9):859-865